Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

More documents

Recommendations

Info

LYMPHOMA RESCUE PROTOCOLS APPENDIX: COMMON CHEMOTHERAPY PROTOCOLS Canine doses (feline doses). If a separate dose is not given for cats, the canine and feline doses are the same. COP CHEMOTHERAPY Weeks 1, 4, 7, 10, 13 and every 3 weeks if complete remission is sustained. Cyclophosphamide 300 mg/m 2 PO Weeks 1–4, 7,10, 13 and every 3 weeks if complete remission is sustained. Vincristine 0.75 mg/m 2 Weeks 1–4 Prednisone 1 mg/kg PO daily. After 4 weeks, prednisone is administered at a rate of 1 mg/kg PO every other day for as long as complete remission is sustained. MULTIAGENT PROTOCOL FOR LYMPHOMA UW- MADISON –25 Week 1 Vincristine 0.7 mg/m 2 (0.05–0.07 mg/m 2 ) IV l-asparaginase 400 mg/m 2 IM Week 2 Cyclophosphamide 250 mg/m 2 (200 mg/m 2 ) IV Week 3 Vincristine 0.7 mg/m 2 (0.05–0.07 mg/m 2 ) IV Week 4 Doxorubicin 30 mg/m 2 (25 mg/m 2 ) IV Week 5 No chemotherapy Weeks 6–9 Repeat weeks 1–4, deleting the l-asparaginase Week 10 No chemotherapy Week 11 Vincristine 0.7 mg/m 2 (0.05–0.07 mg/m 2 ) IV Week 13 Cyclophosphamide 250 mg/m 2 IV (chlorambucil 1.4 mg/kg PO, once) Week 15 Vincristine 0.7 mg/m 2 (0.05–0.07 mg/m 2 ) IV Week 17 Doxorubicin 30 mg/m 2 IV (methotrexate 0.5–0.8 mg/kg IV) Week 19 Vincristine 0.7 mg/m 2 (0.05–0.07 mg/m 2 ) IV Week 21 Cyclophosphamide 250 mg/m 2 IV (chlorambucil 1.4 mg/kg PO, once) Week 23 Vincristine 0.7 mg/m 2 (0.05–0.07 mg/m 2 ) IV Week 25 Doxorubicin 30 mg/m 2 (25 mg/m 2 ) IV Discontinue chemotherapy on week 25 if in complete remission. (For cats, if in complete remission at week 25, treatment should be continued at 3-week intervals following the same sequence of drugs in weeks 11–25. At the end of week 51, and if the cat continues in complete remission, treatment is continued at 4-week intervals substituting methotrexate for doxorubicin) Prednisone start week 1 2 mg/kg PO q.24 h × 7 d 1.5 mg/kg PO q.24 h × 7 d 1.0 mg/kg PO q.24 h × 7 d 0.5 mg/kg PO q.24 × 7 d Discontinue (Cats – prednisone start week 1 2 mg/kg PO daily × 14 d 1 mg/kg PO daily × 7 d 1 mg/kg PO q.48 h for remainder of treatment) LYMPHOMA RESCUE PROTOCOLS MOPP chemotherapy Day 1 and day 8 Methchlorethamine 3 mg/m 2 IV Vincristine 0.7 mg/m 2 (0.25 mg/kg) Days 1–14 Procarbazine 50 mg/m 2 PO (12.5–15 mg/cat daily) Prednisone 30 mg/m 2 PO (5 mg/cat BID PO until protocol discontinuation) Days 14–28 No chemotherapy Repeat cycle beginning day 29 365
CHAPTER 15 CANCER CHEMOTHERAPY D-MAC 14-day cycle Day 1 Dexamethasone, 0.23 mg/kg PO or SC Actinomycin D 0.75 mg/m 2 as IV push Cytarabine 200–300 mg/m 2 as IV drip over 4 h or SC Day 8 Dexamethasone, 0.23 mg/kg PO or SC Melphalan 20 mg/m 2 PO 366
Page 1 and 2:
An imprint of Elsevier Limited © E
Page 3 and 4:
CONTRIBUTORS Matthias J Kleinz Depa
Page 5 and 6:
Dedication To Tom, Rosalind and Jim
Page 7 and 8:
CHAPTER 1 PRINCIPLES OF CLINICAL PH
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
CHAPTER 2 CLINICAL PHARMACOKINETICS
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
CHAPTER 3 ADVERSE DRUG REACTIONS Un
Page 49 and 50:
CHAPTER 3 ADVERSE DRUG REACTIONS to
Page 51 and 52:
CHAPTER 3 ADVERSE DRUG REACTIONS
Page 53 and 54:
CHAPTER 3 ADVERSE DRUG REACTIONS He
Page 55 and 56:
CHAPTER 3 ADVERSE DRUG REACTIONS an
Page 57 and 58:
CHAPTER 3 ADVERSE DRUG REACTIONS wh
Page 59 and 60:
CHAPTER 3 ADVERSE DRUG REACTIONS at
Page 61 and 62:
CHAPTER 3 ADVERSE DRUG REACTIONS Ps
Page 63 and 64:
CHAPTER 3 ADVERSE DRUG REACTIONS su
Page 65 and 66:
CHAPTER 4 THE PHARMACOLOGY OF THE A
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
CHAPTER 5 ANESTHETIC AGENTS However
Page 91 and 92:
CHAPTER 5 ANESTHETIC AGENTS The gre
Page 93 and 94:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 95 and 96:
CHAPTER 5 ANESTHETIC AGENTS doses.
Page 97 and 98:
CHAPTER 5 ANESTHETIC AGENTS ● hig
Page 99 and 100:
CHAPTER 5 ANESTHETIC AGENTS concent
Page 101 and 102:
CHAPTER 5 ANESTHETIC AGENTS X R 3 C
Page 103 and 104:
CHAPTER 5 ANESTHETIC AGENTS Emergen
Page 105 and 106:
CHAPTER 5 ANESTHETIC AGENTS inhalat
Page 107 and 108:
CHAPTER 5 ANESTHETIC AGENTS and enh
Page 109 and 110:
CHAPTER 5 ANESTHETIC AGENTS ● Exc
Page 111 and 112:
CHAPTER 5 ANESTHETIC AGENTS Pharmac
Page 113 and 114:
CHAPTER 5 ANESTHETIC AGENTS Central
Page 115 and 116:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 117 and 118:
CHAPTER 5 ANESTHETIC AGENTS FURTHER
Page 119 and 120:
CHAPTER 6 SEDATIVES ● noradrenali
Page 121 and 122:
CHAPTER 6 SEDATIVES treatment, with
Page 123 and 124:
CHAPTER 6 SEDATIVES Benzodiazepines
Page 125 and 126:
CHAPTER 6 SEDATIVES It is not misci
Page 127 and 128:
CHAPTER 6 SEDATIVES respectively. H
Page 129 and 130:
CHAPTER 6 SEDATIVES Table 6.1 Sugge
Page 131 and 132:
7 Behavior-modifying drugs Kersti S
Page 133 and 134:
CHAPTER 7 BEHAVIOR-MODIFYING DRUGS
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
8 Antibacterial drugs Jill E Maddis
Page 155 and 156:
CHAPTER 8 ANTIBACTERIAL DRUGS phary
Page 157 and 158:
CHAPTER 8 ANTIBACTERIAL DRUGS dose
Page 159 and 160:
CHAPTER 8 ANTIBACTERIAL DRUGS Table
Page 161 and 162:
Page 163 and 164:
CHAPTER 8 ANTIBACTERIAL DRUGS Bacte
Page 165 and 166:
CHAPTER 8 ANTIBACTERIAL DRUGS lacta
Page 167 and 168:
CHAPTER 8 ANTIBACTERIAL DRUGS Antis
Page 169 and 170:
CHAPTER 8 ANTIBACTERIAL DRUGS intri
Page 171 and 172:
Page 173 and 174:
CHAPTER 8 ANTIBACTERIAL DRUGS inter
Page 175 and 176:
CHAPTER 8 ANTIBACTERIAL DRUGS Teico
Page 177 and 178:
CHAPTER 8 ANTIBACTERIAL DRUGS less
Page 179 and 180:
CHAPTER 8 ANTIBACTERIAL DRUGS Diffe
Page 181 and 182:
CHAPTER 8 ANTIBACTERIAL DRUGS forms
Page 183 and 184:
CHAPTER 8 ANTIBACTERIAL DRUGS ● I
Page 185 and 186:
CHAPTER 8 ANTIBACTERIAL DRUGS In an
Page 187 and 188:
CHAPTER 8 ANTIBACTERIAL DRUGS ● R
Page 189 and 190:
CHAPTER 8 ANTIBACTERIAL DRUGS RIFAM
Page 191 and 192:
9 Systemic antifungal therapy Josep
Page 193 and 194:
CHAPTER 9 SYSTEMIC ANTIFUNGAL THERA
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
10 Antiparasitic drugs Stephen W Pa
Page 205 and 206:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 207 and 208:
CHAPTER 10 ANTIPARASITIC DRUGS Tabl
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
CHAPTER 10 ANTIPARASITIC DRUGS leva
Page 217 and 218:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 219 and 220:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 221 and 222:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 223 and 224:
CHAPTER 10 ANTIPARASITIC DRUGS Form
Page 225 and 226:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 227 and 228:
Page 229 and 230:
CHAPTER 10 ANTIPARASITIC DRUGS prod
Page 231 and 232:
CHAPTER 10 ANTIPARASITIC DRUGS Lufe
Page 233 and 234:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 235 and 236:
CHAPTER 10 ANTIPARASITIC DRUGS 62.5
Page 237 and 238:
CHAPTER 10 ANTIPARASITIC DRUGS incr
Page 239 and 240:
CHAPTER 10 ANTIPARASITIC DRUGS rest
Page 241 and 242:
CHAPTER 10 ANTIPARASITIC DRUGS The
Page 243 and 244:
CHAPTER 10 ANTIPARASITIC DRUGS 238
Page 245 and 246:
Page 247 and 248:
CHAPTER 10 ANTIPARASITIC DRUGS In a
Page 249 and 250:
CHAPTER 10 ANTIPARASITIC DRUGS func
Page 251 and 252:
CHAPTER 10 ANTIPARASITIC DRUGS Para
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
CHAPTER 11 GLUCOCORTICOSTEROIDS AND
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
12 Immunomodulatory therapy Michael
Page 277 and 278:
CHAPTER 12 IMMUNOMODULATORY THERAPY
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
CHAPTER 13 NONSTEROIDAL ANTI-INFLAM
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
CHAPTER 14 OPIOID ANALGESICS inflam
Page 317 and 318:
A Agonist opioid (morphine) B Parti
Page 319 and 320: CHAPTER 14 OPIOID ANALGESICS admini
Page 321 and 322: CHAPTER 14 OPIOID ANALGESICS may ac
Page 323 and 324: CHAPTER 14 OPIOID ANALGESICS Small
Page 325 and 326: CHAPTER 14 OPIOID ANALGESICS Clinic
Page 327 and 328: CHAPTER 14 OPIOID ANALGESICS Contra
Page 329 and 330: CHAPTER 14 OPIOID ANALGESICS respon
Page 331 and 332: CHAPTER 14 OPIOID ANALGESICS Advers
Page 333 and 334: CHAPTER 14 OPIOID ANALGESICS Advers
Page 335 and 336: 15 Cancer chemotherapy Jane M Dobso
Page 337 and 338: CHAPTER 15 CANCER CHEMOTHERAPY to m
Page 339 and 340: CHAPTER 15 CANCER CHEMOTHERAPY curr
Page 341 and 342: CHAPTER 15 CANCER CHEMOTHERAPY Tabl
Page 343 and 344: CHAPTER 15 CANCER CHEMOTHERAPY Clin
Page 345 and 346: CHAPTER 15 CANCER CHEMOTHERAPY sion
Page 347 and 348: CHAPTER 15 CANCER CHEMOTHERAPY In t
Page 349 and 350: CHAPTER 15 CANCER CHEMOTHERAPY afte
Page 351 and 352: CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 353 and 354: CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 355 and 356: CHAPTER 15 CANCER CHEMOTHERAPY conc
Page 357 and 358: CHAPTER 15 CANCER CHEMOTHERAPY ●
Page 359 and 360: CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 361 and 362: CHAPTER 15 CANCER CHEMOTHERAPY in t
Page 363 and 364: CHAPTER 15 CANCER CHEMOTHERAPY Adve
Page 365 and 366: CHAPTER 15 CANCER CHEMOTHERAPY best
Page 367 and 368: CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 369: CHAPTER 15 CANCER CHEMOTHERAPY baso
Page 373 and 374: CHAPTER 16 ANTICONVULSANT DRUGS sei
Page 375 and 376: CHAPTER 16 ANTICONVULSANT DRUGS bit
Page 377 and 378: CHAPTER 16 ANTICONVULSANT DRUGS Kno
Page 379 and 380: CHAPTER 16 ANTICONVULSANT DRUGS Mec
Page 381 and 382: CHAPTER 16 ANTICONVULSANT DRUGS rap
Page 383 and 384: CHAPTER 16 ANTICONVULSANT DRUGS exc
Page 385 and 386: 17 Drugs used in the management of
Page 387 and 388: CHAPTER 17 DRUGS USED IN THE MANAGE
Page 421 and 422:
CHAPTER 17 DRUGS USED IN THE MANAGE
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
18 Drugs used in the management of
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
CHAPTER 19 GASTROINTESTINAL DRUGS C
Page 477 and 478:
CHAPTER 19 GASTROINTESTINAL DRUGS r
Page 479 and 480:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 481 and 482:
CHAPTER 19 GASTROINTESTINAL DRUGS c
Page 483 and 484:
CHAPTER 19 GASTROINTESTINAL DRUGS w
Page 485 and 486:
Page 487 and 488:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 489 and 490:
CHAPTER 19 GASTROINTESTINAL DRUGS i
Page 491 and 492:
CHAPTER 19 GASTROINTESTINAL DRUGS L
Page 493 and 494:
CHAPTER 19 GASTROINTESTINAL DRUGS P
Page 495 and 496:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 497 and 498:
Page 499 and 500:
CHAPTER 19 GASTROINTESTINAL DRUGS Z
Page 501 and 502:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 503 and 504:
20 Drugs used in the management of
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
CHAPTER 21 DRUGS USED IN THE TREATM
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534:
23 Drugs and reproduction Philip G
Page 535 and 536:
CHAPTER 23 DRUGS AND REPRODUCTION I
Page 537 and 538:
CHAPTER 23 DRUGS AND REPRODUCTION F
Page 539 and 540:
CHAPTER 23 DRUGS AND REPRODUCTION C
Page 541 and 542:
CHAPTER 23 DRUGS AND REPRODUCTION M
Page 543 and 544:
Page 545 and 546:
CHAPTER 23 DRUGS AND REPRODUCTION n
Page 547 and 548:
CHAPTER 23 DRUGS AND REPRODUCTION E
Page 549 and 550:
Page 551 and 552:
24 Topical dermatological therapy R
Page 553 and 554:
CHAPTER 24 TOPICAL DERMATOLOGICAL T
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
Page 561 and 562:
Page 563 and 564:
CHAPTER 25 OCULAR CLINICAL PHARMACO
Page 565 and 566:
Page 567 and 568:
Page 569 and 570:
Page 571 and 572:
Page 573 and 574:
Page 575 and 576:
Page 577 and 578:
Page 579 and 580:
Index A α-adrenergic receptors 70,
Page 581 and 582:
INDEX Antiplatelet drugs 456-457 pi
Page 583 and 584:
INDEX Ceftazidime 168 Ceftiofur 166
Page 585 and 586:
INDEX Drug receptors 4-8 Drug-drug
Page 587 and 588:
INDEX Hepatic excretion 33 Hepatic
Page 589 and 590:
INDEX Metabolism dogs vs cats 47 an
Page 591 and 592:
INDEX Pentazocine 319, 327 Pentobar
Page 593 and 594:
INDEX Semicarbazone 230 Septic arth
show all

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?